JP2009529502A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529502A5
JP2009529502A5 JP2008557568A JP2008557568A JP2009529502A5 JP 2009529502 A5 JP2009529502 A5 JP 2009529502A5 JP 2008557568 A JP2008557568 A JP 2008557568A JP 2008557568 A JP2008557568 A JP 2008557568A JP 2009529502 A5 JP2009529502 A5 JP 2009529502A5
Authority
JP
Japan
Prior art keywords
dosage form
form according
scyllo
inositol
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000395 external-priority patent/WO2007101353A1/en
Publication of JP2009529502A publication Critical patent/JP2009529502A/ja
Publication of JP2009529502A5 publication Critical patent/JP2009529502A5/ja
Pending legal-status Critical Current

Links

JP2008557568A 2006-03-09 2007-03-09 タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物 Pending JP2009529502A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78052606P 2006-03-09 2006-03-09
US81986406P 2006-07-11 2006-07-11
US89766707P 2007-01-26 2007-01-26
PCT/CA2007/000395 WO2007101353A1 (en) 2006-03-09 2007-03-09 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Publications (2)

Publication Number Publication Date
JP2009529502A JP2009529502A (ja) 2009-08-20
JP2009529502A5 true JP2009529502A5 (enExample) 2011-04-14

Family

ID=38474578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557568A Pending JP2009529502A (ja) 2006-03-09 2007-03-09 タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物

Country Status (14)

Country Link
US (1) US20100113613A1 (enExample)
EP (1) EP1996175A4 (enExample)
JP (1) JP2009529502A (enExample)
KR (1) KR20090026247A (enExample)
CN (1) CN103054837A (enExample)
AU (1) AU2007222864A1 (enExample)
BR (1) BRPI0708725A2 (enExample)
CA (1) CA2644804A1 (enExample)
EA (1) EA200801967A1 (enExample)
IL (1) IL193970A0 (enExample)
MX (1) MX2008011553A (enExample)
NZ (1) NZ571181A (enExample)
WO (1) WO2007101353A1 (enExample)
ZA (1) ZA200908303B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
EP2091566A4 (en) * 2006-11-24 2011-07-06 Waratah Pharmaceuticals Inc COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
DE102007030695A1 (de) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP2014515408A (ja) * 2011-06-03 2014-06-30 エラン ファーマシューティカルズ,リミティド ライアビリティー カンパニー 行動及び精神障害の治療のためのシロ−イノシトール
EP2911664B1 (en) 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
EP3893945A4 (en) 2018-12-10 2022-11-30 The General Hospital Corporation CROMOGLYC ESTERS AND THEIR USES
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE9200547L (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
DE69332542T2 (de) * 1992-10-05 2003-08-14 Virginia Tech Intellectual Properties Inc., Blacksburg Synthesen von d-chiro-3-inosose und (+)-d-chiro-inositol
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
DK0619369T3 (da) * 1993-04-05 2003-10-06 Aveve Nv Phytathydrolyse og enzymsammensætning til hydrolyse af phytat
ES2130440T3 (es) * 1993-08-11 1999-07-01 Hokko Chem Ind Co Proceso para producir d-(quiro)-inositol.
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
RU2002111408A (ru) * 1999-10-18 2004-05-20 Мусклетеч Ресеч Энд Девелопмент Инк. (Ca) Пищевая добавка для увеличения мышечной массы и силы
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US7060695B2 (en) * 2001-02-06 2006-06-13 Qlt, Inc. Method to prevent vision loss
EP1357912B9 (en) * 2001-02-06 2012-06-13 QLT Inc. Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
KR101314079B1 (ko) * 2003-10-14 2013-10-04 혹꼬우 가가꾸 고오교오 가부시끼가이샤 실로-이노시톨의 제조방법
EP1824496A4 (en) * 2004-11-17 2008-07-16 Joanne Mclaurin COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS

Similar Documents

Publication Publication Date Title
JP2009529502A5 (enExample)
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
JP2020023518A5 (enExample)
JP2018513188A5 (enExample)
JP2018520189A5 (enExample)
JP2018507243A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2013511507A5 (enExample)
JP2019517542A5 (enExample)
JP2010509326A5 (enExample)
JP2017132791A (ja) 組み合わせ組成物
JP2010065060A (ja) 心不全処置のための複合治療
JP2015515985A5 (enExample)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2013541583A5 (enExample)
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
JP2017533211A5 (enExample)
JP2016505050A5 (enExample)
CA2563058C (en) Supportive treatment of liver disease
US7825156B2 (en) Method of treating bipolar depression with a benzamide derivative
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
JP2020503318A5 (enExample)
JP6420923B1 (ja) 医薬
JP2015515971A5 (enExample)